Oncothyreon Has Big Plans For Alpine Acquisition
This article was originally published in The Pink Sheet Daily
One Seattle biotech took over another Seattle biotech in hopes of making a stronger oncology player that has the capabilities to develop its own drugs. It also hopes the acquisition will give it more business development opportunities.
You may also be interested in...
In a pair of diabetes-related transaction, Sanofi pays $175 million upfront to MannKind for worldwide license to inhaled insulin Afrezza, while Janssen options Phase I stem cell program from ViaCyte. Novartis gets purchase option for stem-cell biotech Gamida Cell and MorphoSys in-licenses a preclinical prostate cancer antibody candidate from Emergent BioSolutions.
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.
While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.